ArticleCanadian journal of kidney health and disease2026

Eight Years of Canadian Real-World Assessment of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease: The C-MAJOR Registry.

Philip McFarlane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.